Key result
A high biomarker score was associated with a nearly 5-fold increased 5-year risk of heart failure among asymptomatic diabetic patients (OR 4.73; 95% CI 1.84-6.20).
Why the study?
Biomarkers are an alternative approach to detect heart failure risk, but data on this approach are fragmentary in sub-Saharan Africa.
Does a biomarker score predict the risk of heart failure in asymptomatic diabetic patients?
Cross-Sectional (n=408)
No
Does a biomarker score predict the risk of heart failure in asymptomatic diabetic patients?
Odds Ratio: 4.73 (95% CI 1.84–6.2)
A biomarker score incorporating NT-proBNP, hs-CRP, hs-troponin, and left ventricular hypertrophy is strongly associated with the estimated 5-year risk of heart failure in asymptomatic diabetic patients in sub-Saharan Africa.
May support biomarker scoring for HF risk detection in asymptomatic diabetics in sub-Saharan Africa; leaves open need for prospective validation.
Background: The use of biomarkers, such as N-terminal pro-brain natriuretic peptide (NTpBNP), high-sensitivity C-reactive protein (hs-CRP) and high-sensitivity troponin (hs-TnI) is an alternative approach to detect the risk of heart failure (HF), but data on this approach are fragmentary in sub-Saharan Africa. The objective of this study is to determine the correlation between the risk of heart failure and the score of biomarkers in the population of asymptomatic diabetics in the city of GOMA. Methods: Asymptomatic diabetics in the city of Goma were cross-sectionally recruited at the Center of the Association of Diabetics in Congo (ADIC) in Goma, DRC during the period from February 5 to 19, 2023. The risk of insufficiency heart rate at 5 years was determined using pulse pressure. The biomarker score was calculated using NTproBNP, hs-CRP, hs-troponin and left ventricular hypertrophy (LVH). The association between the risk of heart failure and the biomarker score was evaluated using the logistic regression test at the threshold of p < 0.05. Results: Of a total of 408 diabetic patients examined, 29.9% had presented a risk of heart failure. The risk of heart failure was higher in patients with a high biomarker score (57.7%), in patients with type 1 diabetes (60%) and in patients with type 2 diabetes (57.1%). Independent risk of biomarker score on occurrence of heart failure. The risk of heart failure was multiplied by 2 if the biomarker score was intermediate (OR: 2.19, 95% CI: 1.11-4.34) and by 5 if the biomarker score was high (OR: 4.73, 95% CI: 1.84-6.20). Conclusion: The biomarker score is associated with the risk of heart failure in our study via the increase in the score elements as reported in European studies.
No takes yet. Share an insight, caveat, or question.
Mukoso et al. (2024) conducted a cross-sectional in Asymptomatic diabetes (n=408). High biomarker score (NTproBNP, hs-CRP, hs-troponin, LVH) vs. Low or intermediate biomarker score was evaluated on Risk of heart failure at 5 years (OR 4.73, 95% CI 1.84-6.20). A high biomarker score was associated with a nearly 5-fold increased 5-year risk of heart failure among asymptomatic diabetic patients (OR 4.73; 95% CI 1.84-6.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: